GlassScriptPhysician profile
Oladele O Olusanya
NPI 1073542429
$1,586.48
in general payments reported to CMS, 2019-2025
30 companies · $342 in 2025
The $342 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $187 · 2020: $234 · 2021: $148 · 2022: $117 · 2023: $301 · 2024: $257 · 2025: $342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $900.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $900.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $303.51 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $197.44 | 2020-2025 | Trelegy Ellipta |
| Lilly USA, LLC | $139.64 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $97.12 | 2023-2025 | Freestyle Libre |
| Pfizer INC. | $90.36 | 2019-2023 | |
| Amgen INC. | $85.48 | 2020-2025 | Repatha, Otezla, Krystexxa |
| Exact Sciences Corporation | $63.64 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Hologic Sales and Service, LLC | $51.54 | 2022-2024 | Aptima |
| Abbvie INC. | $49.77 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $45.15 | 2019 | |
| Xeris Pharmaceuticals, INC. | $42.15 | 2023 | Gvoke Hypopen |
| Astrazeneca Pharmaceuticals LP | $41.15 | 2020-2025 | Farxiga |
| Dexcom, INC. | $38.07 | 2021-2023 | Dexcom G6 Transmitter |
| Kowa Pharmaceuticals America, INC. | $35.30 | 2024-2025 | Zoryve |
| Sanofi-Aventis U.S. LLC | $33.08 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.12 | 2022-2024 | Xifaxan |
| Valeritas, INC. | $28.41 | 2019 | |
| Alkermes, INC. | $21.63 | 2023 | Vivitrol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.72 | 2025 | Jardiance |
| Eisai INC. | $19.57 | 2020 | |
| Amarin Pharma, INC. | $18.76 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.00 | 2021 | |
| Therapeuticsmd, INC. | $17.48 | 2020 | |
| Idorsia Pharmaceuticals US INC | $16.40 | 2023 | Quviviq |
| Cumberland Pharmaceuticals, INC. | $16.04 | 2024 | Caldolor |
| Cranial Technologies, INC | $15.96 | 2023 | Doc Band |
| Novartis Pharmaceuticals Corporation | $15.57 | 2020 | |
| Smith+Nephew, INC. | $13.68 | 2020 | |
| Janssen Pharmaceuticals, INC | $12.23 | 2021 | |
| Echosens North America, INC. | $9.51 | 2025 | Fibroscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oladele Olusanya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.